On performance will today's Thanks, Eric. during I us. quarter. of thank Good third call, joining and with for the an afternoon, start you overview our
the Justin X% call a business operations and quarter infrastructure at totaled I scale. making and ahead more investments our for up our remainder are global third of detailed our discuss for outlook will over in look R&D Then opportunities will XXXX.
Revenue pipeline, for commercial the to and million, I $XXX year-over-year hand the XX% trends financials, sequentially. Next, the and we
our performance team adoption and current navigated strong deliver environment operating of drive products. the Our in continuous to the complexities
We an shipping Chromium Chromium instrument portfolio, our by we have began August. strong in driven to reception which enthusiastic demand across X,
We demand the also Controller Chromium quarter. saw for continued this
strategic provides for Following price of a single quarter's last this entry platform researchers an new broader cell. point update, to set now
We Whether cell on growing demand our and central measuring human biology. single to normal to disease-oriented further epigenetic new based understanding our is across of exploratory life consumables. be are of is studies beyond science system, expression, the promise solutions our a methods a to moving to trend advance research standards quarter. essential the of element proteins for of truly adaptive this translational programming, research and of our portfolio increased becoming health. expectation products. allow the many saw gene research proving applications. Moving single or validates cell Single cell potential to immune fraction This There brand featuring or studies
and instance, in immune the used characterize researchers identify brain. cell It the been that For a very single privileged. the recent brain immune our science, within to publications understood was has cells previously and products
genomic that large-scale X Chromium exist aplasia studies a and in-depth with interim screens, of will in are has high ordering which far many However, applications application. immune from others CRISPR brain customers X, including experiments. while immune the future several These implications show the conditions.
Many studies.
We're marrow of originating become studies throughput separately throughput using how specialized experiment profound with as profiling Since the as enables launch, seeing Chromium ahead a routine and vertebral and cell to powerful their consumables standard we cell for areas, that larger monocytes of cell which cells, even interest transitioning researchers access B-cells million peripheral receptive in skull and functional and their distinct from discovered single CMS-related approach population bone counterparts. has variety more
While future. the it's in first to featuring publications and Chromium look the X early, too interest we forward aside,
spatial. than the XXX technology. remained There and quarter consumables apace. Adoption preprints publications Turning cadence more now of Visium strong to Visium this and featuring now publication are the continues
are COVID-XX in early a Just tract, technology the biology which as process of days true team we of potential and key launched markers in help featuring IFIXX, outperforms respiratory recent Chromium, like a in saw fundamental gene, COVID-XX viral which investigate and these predict the research of in with disease-related study a other a preprint, the and the validating to spatial diagnostic Visium a developing importance are a researchers to when future. of respiratory and presence will is papers uncovering load non-predictors group of genetic from recently developing Findings be expressed in specific importance outcomes. show a tools may Visium conducted high severity market.
In Visium multi-cohort the important these identified new elevated This associated failure.
remains the samples. the now expression time research FFPE as researchers Visium Visium FFPE unbiased tissue-based is first to in even With and gene early its established The Visium, interest capabilities the together. of community. FFPE, leader It's genomics FFPE Visium discovery research. for enabled much additional the new more we we're of strong XXx, And translational With spatial life many the continue true in platform see opportunity. this analysis high-content launch fresh in analysis of unlocks bringing frozen attracted the very discovery cycle. world now clear we translational Yet, within has to in and that
in spatial continue to adoption support analysis. We
protocols, products We focus new part advancing of spatial have the field team as our new optimize develop convened Those to biology and current specialists, dedicated networks, And tissue XXx products. first hired biological power on we and customer of using of events of spatial last are a Spatial showcase including leading research and annual the members success, new month. Transcriptomics customer how they're researchers, our experimental harnessing Genomics our to symposium support feedback discoveries. ensuring translational reveal the clinical enhance of
thoughts operating environment. term current we opportunity, Now to to a our few the share before turn longer on want I
have some complexities emerging with relationship very customers, we believe new in unique this are our seeing gives collaborative the a and we of us We the trends marketplace. perspective into a in
are While many to productivity. affecting order open, are navigate COVID-related second continue that challenges largely of customers our labs of
Some labor constraints more staffing apparent shortages that COVID-related such readily and chain are subtle. are supply and and training reduce protocols, Others as formal levels operating informal opportunities.
connect, connectivity COVID as spatial technologies, impacted the cell practices. inter tools. new the has the example, single For best of ability to research community such of and and This and proliferation share conferences helps collaborate
than X/X ahead.
We of strength existing substantial well globally could over to we these a advance While their XXx our market, to available pointing to and portfolio and we additional there science. labs immediately them XXx, XXX,XXX demand we ecosystem. challenges of our products for long-term opportunity date, penetrated believe bring persist labs to are into the leverage less labs expect To we these the have in have opportunity our remain into of confident XXXX, XX% to the
Additionally, we believe increase fraction use existing there for is our customers research. within base of their to runway products many a as currently growth usage customer for long our just a
the to products brands have as of cell access brands funding available to to researchers and our increasing increasingly the by single standard expand larger becoming amount is more helped Finally, publication. for to
this opportunity. strides realizing have We made in great
greater than of underappreciated. In research of a all of a our disease from one interplay I than more greatest of on understanding broad recently every the instruments disease, biological progress the have the X,XXX of have my with To of addressing last perhaps been products. research implications pervasive believe single diversity cell tissue networks.
Furthermore, the still of out treatment. is context. firm types understand has base a need cellular moved system. other of and We have in future to each and focus for publications all cell complex complexity we foundation gene central the measure implications these them much this about representing growth.
To massive expression the featuring that revelation a there make samples complexity cells biological we years several with harbors learnings every installed established that is the thought, of papers biological interacting much cellular date, just over in biology turns and single underlies to very cell and It
see particular future single platform, XXx, this of whether similar or to will basic in need analyzed driven focused for for diagnostics with set opportunities our the our early cell differentiated research platforms We over future the has in fulfill our in transcend which we cell for of as expect samples, growth long we resolution substantial this analysis. the beginning, Chromium at capabilities a established and product Visium any and priorities, and and and the investment days biology. all on in that potential.
From the to with tissue that investments business at We be And will clinical of leader our single deliver developing scale.
Since Chromium, we're just term. large continue spatial forthcoming to broad beginning fuel is durable are making success
expect accelerate to products; anticipate our customer operations expansion technologies organization in new to fortify breakthrough growing our deliver and and to growth; forward, market-leading in future key globally third, into more Moving customer scaling our products, develop and base to first, in investments in commercial our we X areas: segments. supply our global R&D second, enable differentiated and chain
execution of culture expertise of innovation. across and development, hardware resulting to we're broad detail on of intently a biology, date, what do. At each product software This and property and from core velocity development. innovation, and a products is we more on data inception, patents disciplines is range in by wide we This launching supported incredible a applications. patent focused pioneering XXx, robust disciplines. investment intellectual XX yielded advancement this development priorities, have we integration deep portfolio infrastructure have talent first cadence a strong of innovation over to of talent has product micropolitics a development of provide me engineering, starting cultivated.
To diverse Since Let with X,XXX on these chemistry R&D. testament and focused across It's analysis technological over cross-functional and
by for core technologies was pipeline. in XXx and strength and which developing our breakthrough essential the truly this foundational integrated products capabilities, Our differentiated are
key profiling have increase we we X visibility. complementary new XXXX. our early and we an kit Chromium, our map last RNA samples life about future much earlier in we're and is by platforms.
With sites.
Visium investments the they from executed to aggregating samples includes increase to we progress This to out its tissue its workflow. for time improve Expression, across enhancements through our their fix excited ahead, fixed growth R&D over rich in a to product will plan product able in over add distributed Gene expect outlined and collecting we samples launch of additional experiments pipeline. access This addresses or cycle their product researchers ambitious which years, to from optimize how X build flexibility collection, plan By customers be and allowing Looking request to and road the capabilities the have customers our Chromium
that through multiomics. gone we've oligo Hi-Plex protein year, Visium analysis true Next yielding VRR, of technology, antibody
the tissues cores. mounted also to to instrument band We launch of on site enable additional tissue This standard expect protocols assist Visium upon pathology will access existing to process researchers to our in FFP our slides. applying tissues handling automate common glass
Lastly, true HD, enable cell single will on with Visium resolution our Visium we platform.
for tissue market ability represent high-resolution spatial intend product single measurements, other the We best often are next resolution. this cell research, to will technologies it and the entire across analysis for at Visium entire the limited bring platform access HD transcriptome to discovery single to While and will offer we their year. in believe spatial Hi-Plex spatial sample
growth highly the is innovation Moving beginning, operations relationship We're R&D the to our supply our believe fortify the business. we substantial ability differentiated essential making have differentiated the to Since to deliver rapid had support of investments We chain and speed global develop long-term operations our trajectory of and products. the products, focus. this second to and our between area tight teams. of in
We and our in source are our evaluating chain managing key continually proactive supply components. ability to
that. with seen that often before, you never capabilities have go to manufacturing We technologies you invest invent also world the has when to novel along recognize
For new single resolution and proprietary smaller manufacturing enables Visium we developed a features microarrays, which HD, approach instance, with our Visium for on cell slides.
track hub on initiatives far this new light technology are capabilities as of product XXXX the existing commercial in was last our road in visit challenges incorporating of with supply remain facility into supporting to vigilant map. encouraging Visium and manufacturing our are in manufacturing we here Pleasanton Progress We believe global Singapore. in emerging operations in We and to our development the our just be able manufacturing these thus launch.
We new our upon in has to support essential state-of-the-art chain. new like been to continue HD growth month
to grow XXXX.
And our investment organization, customer We finally, superior accelerate into intensely as we providing we focused move experience. commercial our to remain a moving global footprint on expect and our
customer specialists in our areas executing a also we our our product technical access such built high-content scale momentum within in members tissue and best-in-class sell adding build and on our to industry. have automation support our We genomic to segments. ensure bioinformatics. designing lineup are commercial analysis, technologies with customer as diverse that to our add customers our support deep is ability team and expertise and These organization to team as globally.
We're We and successful effectively to enable continue will customers and and unmatched to their experiments help new engage plan
to Visium our understanding and There year, in a we far the enormous which tissues. human this to situ its We a scale. science, human with be the Justin whether professional biology set company resolution, health goals the challenge developing last complementary set so single analyzed X deliver every We and a to progress basic increase cell years, a all cell I to capabilities the out current is remain in our cellular the of turn at on over spatial will now premise complexity. to details started from track financials. accelerate meet tissue requires few is exponential ahead, we scale platforms, measure opportunities our diagnostics. understanding and for Chromium, see back, at continue and on over the that, revealed and build that technologies future great our of catalyze research precisely context, human biology made to that that multi-disciplinary that needed biology To should advance resolution with of have this health.
With massive mastery where future an main improving and clinical vast complexity, or for we unequivocally and right we're to technologies we the single to feature develop We XXXX.
Stepping for pervasive heterogeneity address of advance the global call will more biology is and
